Meeting Abstract: 2021 ASCO Annual Meeting I - ASCO Publications Analysis of the phase 3b 4 CheckMate 511 study (NCT02714218) at 1 y showed that NIVO 3 mg kg plus IPI 1 mg kg (NIVO3 + IPI1) improves the safety profile of the combination; efficacy with the 2 regimens was similar in descriptive analyses
Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced . . . The CheckMate 511 trial demonstrated improved tolerability with the flipped dose, NIVO3+IPI1, but this regimen has not been approved in melanoma by regulatory authorities In this study, patients with advanced unresectable melanoma treated with NIVO3+IPI1 or NIVO1+IPI3 were included
Flipped Nivolumab Ipilimumab Dosing Improves Outcomes in Advanced . . . Researchers explored real-world efficacy and safety data for patients with advanced unresectable melanoma treated with the immune checkpoint inhibition combination of nivolumab and ipilimumab and compared the findings by the doses